Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.18885
+0.0236 (14.32%)
At close: Oct 23, 2026, 4:00 PM EDT
0.1699
-0.0189 (-10.03%)
After-hours: Oct 23, 2026, 7:55 PM EDT
Company Description
Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers.
Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression.
The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
Silexion Therapeutics Corp
| Country | Israel |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Ilan Hadar |
Contact Details
Address: 12 Abba Hillel Road Ramat Gan, 5250606 Israel | |
| Phone | 972 3 756 4999 |
| Website | silexion.com |
Stock Details
| Ticker Symbol | SLXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2022416 |
| CUSIP Number | G1281K148 |
| ISIN Number | KYG1281K1489 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ilan Hadar M.B.A. | Chairman and Chief Executive Officer |
| Mirit Horenshtein Hadar | Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific and Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 5, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 29, 2026 | 424B3 | Prospectus |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 28, 2026 | SCHEDULE 13D/A | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 25, 2026 | 8-K | Current Report |
| Sep 25, 2026 | PRE 14A | Other preliminary proxy statements |
| Sep 25, 2026 | 8-K | Current Report |